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Abstract Management strategies are increasingly focused
on tackling the increasing burden of cardiovascular disease
worldwide. Microalbuminuria is a powerful predictor of
cardiovascular disease and mortality in adults. This holds
true in the general adult population but is particularly
recognized in those with diabetes, where it identifies those
likely to develop progressive atherosclerotic vascular
disease and renal impairment. The atherosclerotic process
begins in childhood with likely consequences in later life.
In-depth understanding of the mechanisms through which
microalbuminuria occurs holds promise for designing
therapies to arrest its development in the future. Micro-
albuminuria arises from increased leakage of albumin
through the complex glomerular sieve known as the
glomerular filtration barrier. This requires changes in the
physio-chemical properties of components of this barrier.
However, the increased glomerular permeability confirmed
in disease does not necessarily correlate with recognized
histological changes in the glomerulus, suggesting that
perhaps more subtle ultrastructural changes may be rele-
vant. The epidemiology of microalbuminuria reveals a
close association between systemic endothelial dysfunction
and vascular disease, also implicating glomerular endothe-
lial dysfunction in microalbuminuria. This review discusses
the mechanisms of microalbuminuria in disease, particular-
ly the emerging role of the glomerular endothelium and its
glycocalyx, and examines its implications for cardiovascu-
lar disease in the pediatric population.
Keywords Microalbuminuria.Glomerular filtration
barrier.Endothelial dysfunction.Glomerular endothelial
cell.Glycocalyx
Introduction
The term ‘microalbuminuria’ is a relative misnomer: it
implies ‘small size’ but actually refers to the presence of a
relatively ‘small quantity’ of protein in the urine. The term
was first used nearly 30 years ago when referring to urinary
protein excretion of 30–300 mg per day, which was below
the detection threshold of a standard urine dipstick test [1].
Microalbuminuria is now defined as a urine albumin
excretion (UAE) between 20 and 200 μg/min or 30 to
300 mg in an overnight or 24-h collection. This range of
UAE, although used in the pediatric population, is derived
from population studies in adults.
Relevance of microalbuminuria
The importance of microalbuminuria as an independent
predictor of progressive renal disease and cardiovascular
mortality was thereafter realized in a number of prospective
and epidemiological studies particularly in patients with
diabetes [2–4] and hypertension [5]. In adults, the link
between microalbuminuria, cardiovascular disease, and
progressive renal disease is now well established in patients
with systemic diseases including diabetes mellitus [6].
Interestingly, microalbuminuria has also emerged to be an
important risk factor for the development of cardiovascular
disease, and all cause mortality in the general population
[7]. Faced with the realization of increasing prevalence of
obesity, type 2 diabetes [8], and metabolic syndrome [9]i n
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DOI 10.1007/s00467-011-1777-1children, screening for microalbuminuria seems highly
relevant in the pediatric population to detect and prevent
cardiovascular disease. In this review, we discuss the
current understanding of the pathophysiological mechanism
underlying the appearance of increased albumin in the
urine. We will review the epidemiological studies in
microalbuminuria published regarding children and adoles-
cents and discuss whether the implications for the pediatric
population should be regarded as profound as in those for
adults. During the discussions, we hold with the established
view that increased trans-glomerular passage of albumin is
the major source of microalbuminuria [10].
Methodology used to estimate microalbuminuria
Clinical studies in adults and children have used 24-h,
overnight urine collections and spot urine testing to
estimate UAE. Timed urine collections are generally more
cumbersome in the pediatric population compared to spot
urine testing for estimation for UAE. Simple alternatives
include estimation of urine albumin concentration or
albumin creatinine ratio estimated from spot urine samples.
An albumin-to-creatinine ratio >10 mg/g is diagnostic of
microalbuminuria and is shown to be superior to urine
albumin concentration and comparable to 24-h urine
collections [11, 12]. In adults, the use of the albumin-to-
creatinine ratio particularly in the general population has
been validated in a number of epidemiological studies [13–
15] whereas in children there is relative paucity of such
studies [16]. Due to a wider range of variation in UAE in
children even within the normal range, it is recommended
that the test should be repeated three times annually in
diabetic subjects [17]. The mean albumin-to-creatinine ratio
in normal children>6 years of age seems to fall between
8 and 10 mg/g (males: 7.5 mg/g; females 9.6 mg/g) [18].
Since, UAE is affected by exercise [19] and time of the day
[20], early morning urine sample for the albumin creatinine
ratio provides a more sensitive estimate of microalbumi-
nuria. UAE is estimated to be the lowest in children<6 years
old, followed by an increase through the adolescent years
and a peak at age 15–16 years [16, 18]. Female gender [21],
Tanner stage 4–5 of puberty, height, and weight [22] are all
factors associated with a higher albumin excretion rate in
healthy children. Cross-sectional studies of healthy adoles-
Prevalence of microalbuminuria
Data published from the third National Health and
Nutritional Examination Survey (NHANES) [24] reported
the prevalence of microalbuminuria in a sample of 22,244
subjects aged 6 to >80 years to be 7.8% (6.1% in males and
9.7% in females) with progressively increasing prevalence
in adults >40 years of age. In contrast to the trend in adults,
microalbuminuria among 6–19 year-olds (15%) was noted
to be almost twofold more prevalent than in 20–39 year-
olds adults (7.3%). Also, 6–19-year-old females even had
higher prevalence rates than their male counterparts and
were comparable to 60–79-year-old women. A further
cross-sectional study analyzing the NHANES data for 12–
19-year-old adolescents [25] showed that despite the
presence of cardiovascular risk factors, overweight teen-
agers had a lower prevalence rate of microalbuminuria
compared to healthy controls. Although low, within the
group of obese children with microalbuminuria, there
appeared to be significant association with the presence of
hypertension, insulin resistance, and diabetes. The reason
for the lower prevalence of microalbuminuria in obese
teenagers is uncertain but perhaps lower exercise levels in
obese teenagers leads to less confounding influence by
orthostatic proteinuria [26] . This is opposite to the findings
in adults where a number of studies have shown a positive
relationship of obesity with microalbuminuria [27, 28]. As
expected, microalbuminuria is five-fold more prevalent in
children with diabetes [24].
One obvious explanation for the apparent increase in
prevalence of microalbuminuria in healthy adolescents is
possible confounding influence of orthostatic proteinuria.
This has been reported in 20% of adolescents males [29]
and increases with teenage years but tends to settle
spontaneously after 20 years of age [30]. Orthostatic
proteinuria in isolation is a benign condition and is not
associated with long-term risk of renal disease [31, 32]b u t
with a potential to mask underlying primary kidney
disease [33]. Imaging studies show entrapment of the left
renal vein in the fork between the aorta and proximal
superior mesenteric artery in most cases of postural
proteinuria [34, 35]. This is known as the ‘nutcracker
phenomenon’. Partial obstruction of left renal vein in an
upright position leads rise in glomerular trans-capillary
hydraulic pressure difference and efferent arteriolar resis-
tance leading increased UAE. These hemodynamic
changes are partially mediated via the actions of angio-
tensin II [36]. It is therefore important that orthostatic
proteinuria is considered during assessment of children
and adolescents with microalbuminuria.
Relationship between microalbuminuria
and cardiovascular risk in children
In the adult population, there is indeed mounting evidence
indicating the relationship between microalbuminuria and
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cents have also reported higher albumin excretion in
children of African American descent [23].cardiovascular risk [37]. The threshold level, however, to
define normality in epidemiological studies is inconsistent.
Post-hoc analyses of major clinical trials indicate that an
incremental increase in microalbuminuria, even within the
normal range is associated with an increased rate of cardio-
vascular events in adults [3, 5, 38]. This was also confirmed
in a recent, meta-analysis of 105,872 subjects, which
showed that the hazard ratio for all-cause and cardiovascu-
lar mortality (adjusted for age, genetics, history of CV
disease, systolic blood pressure, diabetes, smoking, and
total cholesterol) rises progressively with increase in UAE
well below the microalbuminuria range, increasing to 1.83
with microalbuminuria in subjects with normal renal
function [39].
The relationship between microalbuminuria and cardio-
vascular disease in the pediatric population is not as well
studied as in adults [18]. There is a clear association
between childhood obesity, elevated blood pressure, and
high fasting insulin levels that persists into adulthood [9].
Childhood obesity, high blood pressure, and hyperlipidemia
are also risk factors for developing atherosclerosis in young
individuals [40]. It is well known that the pre-clinical
atherosclerotic process beginning in childhood has the
potential to be reversed [41]. Microalbuminuria seems to
predict glucose intolerance and metabolic syndrome among
obese children [42, 43]. Data from the Oxford Regional
Prospective Study (ORPS), a population-based study of
children with type 1 diabetes, has shown a significantly
higher (50% compared to 34%) prevalence of micro-
albuminuria in children compared to adults corrected for
glycemic control and duration of diabetes [44]. In their
longitudinal study, Rademacher and colleagues [45]
reported that adolescents with type 1 diabetes have higher
UAE compared to normal healthy controls even prior to
developing microalbuminuria. Body mass index, systolic
blood pressure, and glycemic control predicted the onset of
microalbuminuria and its progression was related to the
duration of diabetes. In their healthy cohort, UAE was not
correlated with an adverse outcome of blood pressure or
insulin resistance [45]. In children with type 1 diabetes,
endothelial dysfunction is known to coincide with micro-
albuminuria [46]. Exposure to hyperglycemia in unrecog-
nized type 2 diabetes is also known to cause vascular
complications earlier, with significantly higher rates of
microalbuminuria at presentation [47, 48]. Interestingly,
maternal blood pressure has been shown to predict micro-
albuminuria in young offspring with diabetes [49]. Type 2
diabetes diagnosed in early youth is associated with worse
outcomes leading to higher rates of diabetic nephropathy
and death, compared to adult-onset type 2 diabetes or non-
diabetics [50]. Microalbuminuria is also a risk factor for
development of left ventricular hypertrophy in adolescents
with essential hypertension [51].
Overall, the evidence linking microalbuminuria and
cardiovascular disease in healthy children is less convincing
than in the adult population. Further studies with long-term
follow-up of healthy children with microalbuminuria are
needed. In obese children, microalbuminuria seems to be a
consistent predictor of insulin resistance and hypertension,
both of which are strong risks for future cardiovascular
disease and death [52]. Again, there are no long-term
studies with follow-up into late adult life to provide direct
estimates of cardiovascular mortality. In children with
diabetes, progression of UAE, (even within the normal
range) starts early and is associated with worse cardiovas-
cular outcomes than adults.
Microalbuminuria as a marker of generalized
endothelial damage
The vascular endothelium, owing to its strategic location
at the interface between flowing blood and other
components of vascular wall, is sensitive to mechanical
stimuli like shear stress and hormonal stimuli, from
vasoactive substances. In response to these varied
stimuli, it releases agents that regulate vasomotor
function and inflammatory processes, and affect homeo-
stasis. Vasodilator substances produced by the endothe-
lium include nitric oxide (NO), prostacyclin, and C-type
natriuretic peptide, which balance the vasoconstricting
effect of endothelin-1, angiotensin II , thromboxane A2,
and reactive oxygen species (ROS) [53]. Endothelial
dysfunction is a well-known contributor to the pathophys-
iology of cardiovascular disease, including hypertension,
coronary artery disease, chronic heart failure, peripheral
artery disease, diabetes, and chronic renal failure [54].
Specific damage of the glomerular endothelial has been
implicated in diseases like hemolytic uremic syndrome,
pre-eclampsia, and acute ischemic renal injury [55–57].
Alteration in endothelial function is known to precede
the development of morphological atherosclerotic changes
and has a primary role in the development of a lesion and
later clinical complications [58]. This process starts early in
childhood [59, 60]. Markers of endothelial dysfunction like
increased capillary permeability are known to be present
well before the onset of microalbuminuria in type 1
diabetes and also show evidence of progression in
association with it [61, 62]. This is difficult to establish in
type 2 diabetes as it is often complicated by the presence of
other risk factors for vascular disease at presentation and
discerning the relationship of hyperglycemia and its
sequelae to endothelial dysfunction is difficult. Although
microalbuminuria may occur without the evidence of
endothelial dysfunction, von Willebrand Factor levels, a
marker of endothelial dysfunction, can predict its develop-
Pediatr Nephrol (2011) 26:1957–1965 1959ment [63]. The link between endothelial dysfunction and
microalbuminuria in type 1 diabetes seems to be important
in predicting the development of diabetic nephropathy and
susceptibility to micro- and macrovascular disease.
Endothelial dysfunction, as an important antecedent of
microalbuminuria in both types of diabetes, provides an
attractive explanation for the association between micro-
albuminuria and vascular disease in diabetes, but is
endothelial dysfunction enough to cause a breach in the
sieving action of kidney leading to microalbuminuria?
Glomerular endothelium is exposed to the same diabetic
microenvironment as other endothelia, and it is highly
likely that as a result of this exposure, it also becomes
dysfunctional. Whether dysfunction of the glomerular
endothelium can lead to microalbuminuria will be better
understood once we consider the structure and function of
the glomerular filtration barrier (GFB) in the next section.
Glomerular filtration barrier as a complex sieve
Glomerular capillaries are highly specialized and have high
permeability to water (hydraulic conductivity) and small
solutes yet, are highly resistant to the escape of macro-
molecules (like albumin) in urine [64]. These properties are
as a result of a unique, three-layer structure (Fig. 1) known
as the glomerular filtration barrier (GFB). The GFB on the
luminal side of the capillary is comprised of fenestrated
glomerular endothelium with its glycocalyx, podocytes
(glomerular visceral epithelial cells) on urinary side and
glomerular basement membrane (GBM), which is sand-
wiched between the two cell types [65]. The GFB is
primarily responsible for the sieving action of the kidney
and in the healthy filters approximately 80 l of plasma
every day.
Podocytes, or more specifically their inter-digitating foot
processes, form the outer layer of the GFB (Fig. 1). The
gaps between adjacent foot processes, known as the
‘filtration slits’ (25–60 nm), are spanned by the slit
diaphragm. This is like a molecular scaffold thought to
form the most restrictive barrier to water and macromolec-
ular passage [66]. The effect of mutations in podocyte-
specific proteins, which form the complex slit diaphragm
(e.g., nephrin, mutations result in congenital nephrotic
syndrome), indicate the importance of podocytes in
restricting the passage of protein [67]. Alterations in
Fig. 1 Schematic drawing of components of the glomerular filtration
barrier (GFB). Fenestrated glomerular endothelial cells (GEnC) form
the luminal side of the sieve and facilitate the high flux of water and
small molecules (blue arrows); glomerular basement membrane
(GBM) in the middle, and the podocyte foot processes and slit
diaphragms on the urinary side. The GEnC (including the fenestrae)
are covered by a mesh-like, anionic layer of glycocalyx composed of
sialic acid-rich glycoproteins and proteoglycans consisting of core
proteins and attached branching glycosaminoglycan chains (mainly
heparan sulphate and chondroitin sulphate). The glycosaminoglycan
hyaluronan is non-covalently bound to the cell surface and other
glycocalyx components. Adsorbed plasma proteins including albumin
(yellow dots) and orosomucoid (purple dots) contribute to the high
negative charge of the glycocalyx layer. In the healthy, all the three
components of the GFB work together and conserve 99.9% of proteins
in the capillary lumen
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process, are a common histological abnormality seen in
kidney biopsy specimens and is associated with proteinuric
kidney diseases including diabetes. Although discrete
effacement of the podocyte foot process is an indicator of
podocyte injury, it is an unreliable predictor of mild protein
excretion [68–70].
The glomerular basement membrane (GBM) is a basal
lamina specialized for the structural requirements of the
GBM and its filtration function. It is a hydrated meshwork
of collagens and laminins to which are attached negatively
charged proteoglycans. Traditional concepts have therefore
characterized the GBM as a charge-selective barrier.
However, more recent analyses indicate that its contribution
to the barrier to protein passage is small [65].
Glomerular endothelial cells are adapted to enable the
high hydraulic conductivity of the GFB, necessary for
filtration. These highly specialized cells have areas of
numerous circular transcellular pores 60–80 nm in diameter
[65, 71, 72] referred to as fenestrae. Initially these
fenestrations were thought of as ‘empty’ and therefore
providing little resistance to the passage of proteins.
Advances in fixation techniques in electron microscopy
have allowed the demonstration of glomerular endothelial
glycocalyx which is 200–400 nm in thickness [73]. The
glycocalyx covers both fenestral and inter-fenestral
domains of the glomerular endothelial cell luminal surface
at the interface of the endothelium and the blood flow [74].
The glycocalyx is a dynamic hydrated layer largely
composed of glycoproteins and proteoglycans with
adsorbed plasma proteins. Proteoglycans, particularly hep-
aran sulphate proteoglycans (HSPG), are largely responsi-
ble for the anionic charge characteristics of the glycocalyx.
Selective removal of endothelial glycocalyx from coronary
vessels increases permeability providing evidence that it
constitutes a barrier to macromolecular permeability [75].
Therefore, the presence of a significant glomerular
endothelial glycocalyx implies that the glomerular endo-
thelium contributes significantly to the barrier to macro-
molecules [76, 77]. Experimental data certainly supports
this view. Mice treated with glycocalyx-degrading enzymes
show reduction in thickness of glomerular endothelial
glycocalyx coinciding with increased albumin excretion
[78]. In rats, under physiological perfusion conditions,
albumin is confined to the glomerular capillary lumen and
endothelial fenestrae, implying resistance at the level of
glomerular endothelial surface [79]. Endothelial glycocalyx
has the correct anatomical distribution (on the surface of
endothelial cells including in fenestral openings) to explain
this distribution. Reactive oxygen species (ROS), which are
known to damage the glycocalyx [80], cause heavy
proteinuria without any identifiable structural changes in
the GFB using standard electron microscopy techniques
[81]. Interestingly, a recent study showed that disruption of
glomerular endothelial glycocalyx by induction of ROS can
cause proteinuria [82]. Furthermore the ability of human
glomerular endothelial cell glycocalyx to form a perme-
ability barrier to macromolecules can also be directly
demonstrated in vitro [77].
Structural and functional alterations in GFB associated
with microalbuminuria
Even though the glomerular structural changes typical of
glomerular diseases like diabetic nephropathy are common-
ly established by the time microalbuminuria becomes
apparent [83], these changes are heterogeneous and can be
found in patients without microalbuminuria [70]. Early
changes include an increase in glomerular size, thickening
of the GBM, expansion of the mesangium, and effacement
of podocyte foot processes [70, 83] .T h ei n c r e a s ei n
glomerular size is due both to mesangial expansion and to
enlargement in glomerular capillaries due to hemodynamic
changes. Glomerular structural changes are less marked in
type 2 diabetes, with only a third conforming to the
classical pattern observed in type 1 diabetes [84].
Effacement of podocyte foot processes is an indicator of
podocyte injury, but an unreliable predictor of protein
excretion. Surely, proteinuria can occur in complete
absence of structural changes in podocytes [85]. This is
particularly evident in diabetic microalbuminuria associated
with type 2 diabetes where podocyte ultrastructure may be
unchanged [86]. Perhaps a likely explanation to reconcile
this issue is that the lower proportion of podocytes seen in
early disease is due to an increase in mesangial and
endothelial cells while podocyte loss occurs at a later stage.
As discussed in the previous section, the hypothesis
brought forward is that glomerular endothelial glycocalyx is
well placed to play an important role in the pathogenesis of
microalbuminuria. There is emerging evidence showing
that total systemic glycocalyx volume is reduced by acute
hyperglycemia in human subjects [87]. Also, type 1
diabetics have reduced systemic glycocalyx volume, which
coincides with the onset of microalbuminuria [88]. GBM
thickening alone, without change in composition, does not
significantly affect its protein permeability characteristics.
Increased passage of albumin across the GFB in diabetic
microalbuminuria can be confirmed in experimental mod-
els. Detailed analysis of permeability characteristics of the
GFB to molecules of varying size and charge has been used
to estimate whether the increased flux of albumin is due to
loss of size or charge selectivity of the GFB. In the animal
models of diabetes the primary defect seems to be in charge
selectivity [89], but in healthy non-diabetic individuals with
microalbuminuria, loss of both charge and size selectivity
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defects in charge-selectivity occur earlier than loss of size
selectivity [86, 91].
Conclusions
In summary, microalbuminuria in the healthy pediatric
population appears to be more prevalent than in young
adults. Obesity is an established risk factor for diabetes and
metabolic syndrome. However, obese children in the
absence of diabetes do not have a higher prevalence of
microalbuminuria. Microalbuminuria in non-diabetic and
non-obese children is not associated with cardiovascular
risk factors. In contrast, in obese children, cardiovascular
r i s kf a c t o r ss u c ha si m p a i r e df a s t i n gg l u c o s e ,i n s u l i n
resistance, and hypertension are strongly associated with
microalbuminuria. This shows that the association between
cardiovascular risk factors and microalbuminuria is strongly
modified by being overweight.
Unlike the literature in adults, there is a paucity of clinical
evidencefromlongitudinalstudiesthatanalyzesthelong-term
cardiovascular risks in healthy children with microalbuminu-
ria. In diabetic children, the onset and progression of micro-
albuminuria carries a similar prognostic profile to adults.
Microalbuminuria is an indicator of generalized endothelial
dysfunctionandisregardedasacommonpathwayofinjuryto
both renal and systemic vascular beds. Progression of micro-
albuminuria to overt nephropathy is accompanied by predict-
able structural changes in the glomerulus including loss and
damage to the podocyte. The endothelial glycocalyx, apart
from acting as a barrier to protein permeability, also protects
the endothelium against atherosclerosis [92]. Disturbance of
the endothelial glycocalyx as the common process underly-
ing both microalbuminuria and generalized endothelial
dysfunction is the most plausible explanation for the
profound cardiovascular complications seen in these
patients.
The evidence from studies in the pediatric population
does not provide clear estimates of cardiovascular risks
in relatively healthy children who develop microalbumi-
nuria and clearly further epidemiological studies are
necessary to determine its ramifications. Therefore,
currently widespread screening in the pediatric popula-
tion cannot be justified. However, studies so far provide
enough evidence to suggest that microalbuminuria in
obese children, even in the absence of diabetes, should
be taken as seriously as in diabetic children. We
recommend that overweight children and parents should
be motivated early on and engaged for lifestyle advice
(exercise, cessation of smoking, diet) with close moni-
toring. Evidence from small studies suggests that early
intervention with ACE inhibitor therapy is likely to be
beneficial [93, 94]. The Adolescent type 1 Diabetes
cardio-renal Intervention Trial (AdDIT) is an ongoing
multi-center, randomized, double-blind clinical trial that
will hopefully report on the use of ACE inhibitor and
statin therapy in adolescents with type 1 diabetes and
hopefully provide long-term data on cardiovascular out-
comes after this intervention [95]. Clinicians should also
give careful consideration to progression of UAE rather
than being rigid about the threshold for microalbuminuria.
Finally, we hope that with increasing understanding of
the molecular mechanisms of microalbuminuria, novel
therapies will be designed that prevent and reverse
endothelial dysfunction association with microalbuminuria
and the resultant cardiovascular disease.
Multiple-choice questions (answers appear following the
reference list):
1. Inestimatingmicroalbuminuria, the followingstatement
is true:
a) early morning spot urine for albumin creatinine
ratio is the best
b) 24-h urine collection should always be done when
possible
c) urine protein creatinine ratio is as reliable as the
urine albumin creatinine ratio
d) the standard urine dip stick in the clinic is equally
reliable
2. The estimates of prevalence of microalbuminuria in
children are:
a) higher compared to young adults
b) higher in girls and children from an ethnic
background
c) are likely confounded by the effects of orthostatic
proteinuria
d) all of the above
3. Postural or orthostatic proteinuria
a) is not a benign condition and indicates progressive
kidney disease
b) more common in obese girls
c) mostly associated with ‘nutcracker syndrome’
d) should be managed with ACE inhibitors
4. Generalized endothelial dysfunction is
a) rarely seen in children
b) usually precedes the onset of microalbuminuria
c) is reversed in early adult life
d) is exclusively seen in diabetic children
5. The glomerular endothelial glycocalyx layer
a) is a dynamic layer that is produced by glomerular
endothelial cells
b) is vulnerable to damage in systemic diseases
c) is an important contributor to resistance to protein
permeability
d) all of the above
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